JPMorgan Chase & Co. lessened its position in Repligen Co. (NASDAQ:RGEN - Free Report) by 96.4% during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 363,499 shares of the biotechnology company's stock after selling 9,681,000 shares during the period. JPMorgan Chase & Co. owned approximately 0.65% of Repligen worth $54,096,000 at the end of the most recent reporting period.
Other institutional investors have also modified their holdings of the company. Champlain Investment Partners LLC raised its position in Repligen by 149.0% in the third quarter. Champlain Investment Partners LLC now owns 1,420,935 shares of the biotechnology company's stock worth $211,464,000 after acquiring an additional 850,345 shares in the last quarter. Thrivent Financial for Lutherans grew its stake in shares of Repligen by 6.1% in the 3rd quarter. Thrivent Financial for Lutherans now owns 638,602 shares of the biotechnology company's stock worth $95,037,000 after purchasing an additional 36,773 shares during the last quarter. DF Dent & Co. Inc. raised its holdings in shares of Repligen by 31.0% in the 3rd quarter. DF Dent & Co. Inc. now owns 590,321 shares of the biotechnology company's stock worth $87,852,000 after purchasing an additional 139,615 shares in the last quarter. New York State Common Retirement Fund lifted its stake in Repligen by 14.4% during the third quarter. New York State Common Retirement Fund now owns 567,044 shares of the biotechnology company's stock valued at $84,387,000 after purchasing an additional 71,274 shares during the last quarter. Finally, Dimensional Fund Advisors LP boosted its holdings in Repligen by 39.4% during the second quarter. Dimensional Fund Advisors LP now owns 429,524 shares of the biotechnology company's stock worth $54,149,000 after buying an additional 121,305 shares in the last quarter. Institutional investors and hedge funds own 97.64% of the company's stock.
Wall Street Analysts Forecast Growth
Several research analysts have issued reports on RGEN shares. Canaccord Genuity Group began coverage on Repligen in a report on Tuesday, December 17th. They issued a "hold" rating and a $165.00 price target on the stock. Wolfe Research started coverage on Repligen in a report on Thursday, November 14th. They issued a "peer perform" rating on the stock. StockNews.com raised Repligen from a "sell" rating to a "hold" rating in a report on Friday. Royal Bank of Canada reissued an "outperform" rating and issued a $205.00 price target on shares of Repligen in a research note on Thursday, September 26th. Finally, Canaccord Genuity Group began coverage on shares of Repligen in a research note on Tuesday, December 17th. They set a "hold" rating and a $165.00 price objective for the company. Six investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company's stock. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $185.20.
Check Out Our Latest Stock Analysis on RGEN
Repligen Stock Up 4.8 %
Shares of NASDAQ RGEN traded up $6.85 during mid-day trading on Friday, reaching $149.90. The company had a trading volume of 504,733 shares, compared to its average volume of 401,016. The stock has a market capitalization of $8.40 billion, a PE ratio of -405.12, a price-to-earnings-growth ratio of 4.64 and a beta of 0.97. Repligen Co. has a twelve month low of $113.50 and a twelve month high of $211.13. The company has a debt-to-equity ratio of 0.26, a quick ratio of 8.76 and a current ratio of 10.44. The stock's 50 day moving average is $144.96 and its 200-day moving average is $142.34.
Repligen (NASDAQ:RGEN - Get Free Report) last posted its quarterly earnings results on Tuesday, November 12th. The biotechnology company reported $0.43 earnings per share for the quarter, topping analysts' consensus estimates of $0.34 by $0.09. The company had revenue of $154.87 million during the quarter, compared to the consensus estimate of $153.34 million. Repligen had a positive return on equity of 3.90% and a negative net margin of 3.36%. The business's quarterly revenue was up 9.7% on a year-over-year basis. During the same period last year, the business earned $0.23 EPS. As a group, equities analysts anticipate that Repligen Co. will post 1.54 earnings per share for the current fiscal year.
About Repligen
(
Free Report)
Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.
Read More
Before you consider Repligen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Repligen wasn't on the list.
While Repligen currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
